TRAW (Traws Pharma) Operating Margin %: 0.00% (As of Mar. 2026)


TRAW Traws Pharma Inc TRAW
49 GF Score
Price $0.83
GF Value $12.92
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Traws Pharma Operating Margin %?

Traws Pharma TRAW 49 Operating Margin % is 0.00% as of Mar. 2026. GuruFocus rates TRAW with a GF Score™ of 49/100 and a GF Value™ of $12.92 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 944 Biotechnology companies, Traws Pharma ranks worse than 74.79% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Traws Pharma's Operating Income for the three months ended in Mar. 2026 was $-6.95 Mil. Traws Pharma's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Traws Pharma's Operating Margin % for the quarter that ended in Mar. 2026 was 0.00%.

Good Sign:

Traws Pharma Inc operating margin is expanding. Margin expansion is usually a good sign.

The historical rank and industry rank for Traws Pharma's Operating Margin % or its related term are showing as below:

TRAW' s Operating Margin % Range Over the Past 10 Years
Min: -11022.12   Med: -5284.7   Max: -427.39
Current: -717.82


TRAW's Operating Margin % is ranked worse than
74.79% of 944 companies
in the Biotechnology industry
Industry Median: -86.83 vs TRAW: -717.82

Traws Pharma's 5-Year Average Operating Margin % Growth Rate was 30.80% per year.

Traws Pharma's Operating Income for the three months ended in Mar. 2026 was $-6.95 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was $-19.62 Mil.


Traws Pharma  (NAS:TRAW) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Traws Pharma Operating Margin % Related Terms


Traws Pharma Operating Margin % Historical Data

* Premium members only.

The historical data trend for Traws Pharma's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Traws Pharma Operating Margin % Chart

Traws Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7,299.12 -8,684.51 -8,981.42 -11,022.12 -640.68

Traws Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9,128.07 -45.70 0.00 0.00 0.00

TRAW vs CVM, CRIS, QNCX: Operating Margin % Comparison

For the Biotechnology subindustry, Traws Pharma's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Traws Pharma Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Traws Pharma's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Traws Pharma's Operating Margin % falls into.


TRAW
49GF Score
Traws Pharma Inc TRAW
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Traws Pharma Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Traws Pharma's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-17.875 / 2.79
=-640.68 %

Traws Pharma's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=-6.946 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 0.00% mean?
Traws Pharma (TRAW) has a Operating Margin % of 0.00% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Traws Pharma and its competitors. According to the industry distribution chart, Traws Pharma ranks #706 out of 944 companies in the Biotechnology industry, placing it in the top 74.8%.
Is Traws Pharma's Operating Margin % too high?
Traws Pharma's current Operating Margin % is 0.00%. Based on the distribution chart, Traws Pharma ranks #706 out of 944 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Traws Pharma has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Traws Pharma's Operating Margin % compare to CVM and CRIS?
According to the Biotechnology industry distribution chart, Traws Pharma ranks #706 out of 944 companies for Operating Margin %. This places Traws Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Traws Pharma and its competitors. Traws Pharma's current Operating Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Traws Pharma stock overvalued right now?
Based on GuruFocus' analysis, Traws Pharma (TRAW) is currently considered Possible Value Trap. The stock's GF Value™ is $12.92, compared to a current price of $0.83 — trading 93.6% below its estimated fair value. The current Operating Margin % is 0.00%. Traws Pharma's overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Traws Pharma (TRAW), the current Operating Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Traws Pharma (TRAW) Overvalued in 2026?

Based on GuruFocus' analysis, Traws Pharma stock appears to be undervalued. The current stock price of $0.83 is trading 93.6% below its estimated GF Value™ of $12.92. GuruFocus considers Traws Pharma to be Possible Value Trap.

Key valuation signals for TRAW:

  • Operating Margin %: 0.00%
  • GF Value™: $12.92 vs. price of $0.83 (93.6% below fair value)
  • GF Score™: 49/100 with 4 warning signs

No single metric tells the full story. See the TRAW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Traws Pharma Business Description

Address 12 Penns Trail, Newtown, PA, USA, 18940
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.
49GF Score

Get the complete analysis for TRAW

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.83
Price
$12.92
GF Value